LIST OF Supplementary data

Supplementary data 1: Table S1. Baseline characteristics and treatment pattern at Year 1 in safety set and primary treated eye set of patients with PCV

Supplementary data 2: Figure S1. Mean change in central retinal thickness at Month 12 in primary treated eye set by pre-treatment status

Supplementary data 3: Figure S2. Mean change in central retinal thickness at Month 12 in primary treated eye set by PCV status

Supplementary data 4: Table S2. Patients with ocular and non-ocular adverse events at 5 years: Safety and primary treated eye set

Supplementary data 5: Table S3. Adverse events suspected to be related to ranibizumab treatment and/or ocular injection over a 5-year period in the primary treated eye set

Supplementary data 6: Table S4. Patients with ocular and non-ocular adverse events at 1 years: Safety and primary treated eye set

Supplementary data 7: Table S5. The LUMINOUS study investigators from South Korea

Table S1. Baseline characteristics and treatment pattern at Year 1 in safety set and primary treated eye set of patients with PCV

Characteristics	Treatment-naïve		*P value*	Prior-treated		*P value*
	PCV n=48	**Non-PCV n=104**		**PCV n=57**	**Non-PCV n=158**	
Patient demographics						
Mean (SD) age, years	68.4 (8.2)	73.9 (9.2)	0.0006	68.7 (8.2)	71.8 (8.1)	0.0161
Gender, n (%)						
Male	34 (70.8)	69 (66.4)	0.5822	44 (77.2)	100 (63.3)	0.0557
Ocular characteristics						
CNV type, n (%)			0.0156			0.0053
Predominantly classic	6 (12.5)	32 (30.8)		5 (8.8)	42 (26.6)	
Minimally classic/occult	42 (87.5)	72 (69.2)		52 (91.2)	116 (73.4)	
PED, n (%)	33 (68.8)	73 (70.2)	0.8572	35 (61.4)	104 (65.8)	0.5496
RAP, n (%)	1 (2.1)	5 (4.8)	0.4227	2 (3.5)	4 (2.5)	0.7010
Lesion size, %			0.8596			0.8008
≤1 DA	15 (31.3)	34 (32.7)		22 (38.6)	64 (40.5)	
>1 DA	33 (68.8)	70 (67.3)		35 (61.4)	94 (59.5)	
VA						
n	47	100		47	146	
Mean (SD) VA, ETDRS letters	49.0 (24.37)	40.4 (26.83)	0.0630	58.5 (17.13)	52.9 (22.34)	0.0732
CRT						
n	43	88		40	123	
Mean (SD) CRT, µm	396.2 (156.18)	415.5 (147.81)	0.1003	289.6 (80.61)	288.6 (88.72)	0.9472
IOP						
n	45	80		46	132	
Mean (SD), mmHg	13.6 (3.38)	14.1 (3.95)	0.4487	14.5 (3.35)	14.5 (3.55)	0.9321
Treatment pattern						
Median time from diagnosis to first	3.5	5.0	0.1304	278.0	176.5	0.1998

treatment, days (min, max)	(1.00, 3062.00)	(1.00. 218.00)	(1.00. 3565.00)	(1.00. 4075.00)

Indication and pre-treatment status refers to the primary treated eye

The safety set comprised patients in the enrolled set who were treated with at least one dose of ranibizumab during the study or prior to study initiation and had at least one safety assessment post-initial treatment.

Primary treated eye set included all primary treated eyes in patients included in the safety set

Patients with a baseline visit date on or before March 2015 are included. Data collected until the last recorded follow-up date were used to perform the analyses

Two-sided student's t-test was performed to compare the baseline demographics and patient characteristics between PCV and non-PCV patients.

CRT, central retinal thickness; DA, disc area; ETDRS, Early Treatment Diabetic Retinopathy Study; IOP, intraocular pressure; N, total number of patients; n, number of patients; nAMD, neovascular age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; SD, standard deviation

Figure S1. Mean change in CRT at M12 in primary treated eye set by pre-treatment status



Primary treated eye set included all primary treated eyes in patients included in the safety set

Statistical analyses were performed using two-sample student's t-tests to compare CRT between baseline and Year 1. *P<0.05, ***P<0.001

CRT, central retinal thickness; N, total number of patients; n, number of patients; M, month, PCV, polypoidal choroidal vasculopathy

Figure S2. Mean change in CRT at M12 in primary treated eye set by PCV status



Primary treated eye set included all primary treated eyes in patients included in the safety set

Two-sample student's t-test was performed to compare the mean change in VA between patients with/without PCV

CRT, central retinal thickness; n, number of patients; M, month, PCV, polypoidal choroidal vasculopathy; VA, visual acuity

Table S2. Patients with ocular and non-ocular adverse events (5 years): Safety and primary treated eye set

Preferred term, n (%)	Treatment-naïve n=152	Prior-treated n=215	Total N=367
Ocular AEs, total	**16 (10.5)**	**15 (7.0)**	**31 (8.4)**
Cataract	3 (2.0)	5 (2.3)	8 (2.2)
Conjunctival haemorrhage	4 (2.6)	1 (0.5)	5 (1.4)
Dry eyes	3 (2.0)	2 (0.9)	5 (1.4)
Conjunctivitis allergic	3 (2.0)	1 (0.5)	4 (1.1)
Posterior capsule opacification	2 (1.3)	0 (0.0)	2 (0.5)
Vitreous haemorrhage	2 (1.3)	0 (0.0)	2 (0.5)
Non-ocular AEs, total	**18 (11.8)**	**19 (8.8)**	**37 (10.1)**
Gastric ulcer	2 (1.3)	0 (0.0)	2 (0.5)
Large intestine polyp	0 (0.0)	2 (0.9)	2 (0.5)
Herpes zoster infection	2 (1.3)	1 (0.5)	3 (0.8)
Dizziness	2 (1.3)	0 (0.0)	2 (0.5)
Headache	1 (0.7)	1 (0.5)	2 (0.5)
Diabetes mellitus	0 (0.0)	2 (0.9)	2 (0.5)
Anaemia	1 (0.7)	1 (0.5)	2 (0.5)
Insomnia	2 (1.3)	0 (0.0)	2 (0.5)
Hypertension	0 (0.0)	2 (0.9)	2 (0.5)

Ocular AEs were assessed for the primary treated eye set and non-ocular AEs were assessed for the safety set

The safety set comprised patients in the enrolled set who were treated with at least one dose of ranibizumab during the study or prior to study initiation and had at least one safety assessment post-initial treatment.

Primary treated eye set included all primary treated eyes in patients included in the safety set

Indication and pre-treatment status refers to the primary treated eye. Only AEs occurring during the safety observation period are included. Preferred terms are presented by descending order of frequency in the total column. A patient with multiple occurrences of an AE was counted once per preferred term. A patient with multiple AEs is counted only once in the total row. Patients with a baseline visit date present are included. Data collected until the last recorded follow-up date were used to perform the analyses. Total ocular and non-ocular AEs >2 in number are shown

AE, adverse event; N, total number of patients; n, number of patients

Table S3. AEs suspected to be related to ranibizumab treatment and/or ocular injection over a 5-year period in the primary treated eye set

Preferred term, n (%)	Treatment-naïve n=152	Prior-treated n=215	Total n=367
Ocular AEs, total	**3 (2.0)**	**0 (0.0)**	**3 (0.8)**
Conjunctival haemorrhage	3 (2.0)	0 (0.0)	3 (0.8)
Cataract	1 (0.7)	0 (0.0)	1 (0.3)

The primary treated eye set included all primary treated eyes in patients included in the safety set
Indication and pre-treatment status refers to the primary treated eye. Only AEs occurring during the safety observation period are included. Preferred terms are presented by descending order of frequency in the total column. A patient with multiple occurrences of an AE was counted once per preferred term. A patient with multiple AEs is counted only once in the total row. Patients with a baseline visit date present are included. Data collected until the last recorded follow-up date were used to perform the analyses
AE, adverse event; n, number of patients

Table S4. Patients with ocular and non-ocular AEs (1 year): Safety and primary treated eye set

Preferred term, n (%)	Treatment-naïve n=152	Prior-treated n=215	Total N=367
Ocular AEs, total	**12 (7.9)**	**11 (5.1)**	**23 (6.3)**
Cataract	1 (0.7)	4 (1.9)	5 (1.4)
Conjunctival hemorrhage	4 (2.6)	1 (0.5)	5 (1.4)
Dry eyes	2 (1.3)	2 (0.9)	4 (1.1)
Conjunctivitis allergic	2 (1.3)	1 (0.5)	3 (0.8)
Posterior capsule opacification	2 (1.3)	0 (0.0)	2 (0.5)
Non-ocular AEs, total	**14 (9.2)**	**12 (5.6)**	**26 (7.1)**
Herpes zoster infection	2 (1.3)	0 (0.0)	2 (0.5)
Dizziness	1 (0.7)	0 (0.0)	1 (0.3)
Headache	1 (0.7)	1 (0.5)	2 (0.5)
Diabetes mellitus	0 (0.0)	2 (0.9)	2 (0.5)
Anaemia	1 (0.7)	0 (0.0)	1 (0.3)
Insomnia	1 (0.7)	0 (0.0)	1 (0.3)

Ocular AEs were assessed for the primary treated eye set and non-ocular AEs were assessed for the safety set

The safety set comprised patients in the enrolled set who were treated with at least one dose of ranibizumab during the study or prior to study initiation and had at least one safety assessment post-initial treatment.

Primary treated eye set included all primary treated eyes in patients included in the safety set

Indication and pre-treatment status refers to the primary treated eye. Only AEs occurring during the safety observation period are included. Preferred terms are presented by descending order of frequency in the total column. A patient with multiple occurrences of an AE was counted once per preferred term. A patient with multiple AEs is counted only once in the total row. Patients with a baseline visit date present are included.

Data collected until the last recorded follow-up date were used to perform the analyses

AE, adverse event; N, total number of patients; n, number of patients

Table S5. The LUMINOUS study investigators from South Korea

Investigator	Affiliation
Dr Hakyoung Kim	Hallym University Kangnam Sacred Heart Hospital, Seoul, 150-950, Korea
Dr So Hyun Bae	
Dr Hyeong-Gon Yu	Seoul National University Hospital, Seoul, Gyeonggi-do, 110744, Korea
Dr Jang-Won Heo	
Dr Joo Young Shin	
Dr In Hwan Cho	
Dr Hyoung Jun Koh	Gangnam Severance Hospital, Yonsei University Health System, Seoul, 062 73, Korea
Dr Yong Woo Ji	
Dr Hyun Woong Kim	Inje University Busan Paik Hospital, Busan, 47392, Korea
Dr Young Jin Kim	
Dr Seung-Young Yu	Kyung Hee University Hospital, Seoul, 024 47, Korea
Dr Yonguk Kim	
Dr Minseok Kang	
Dr Kyunghoon Seo	
Dr Kiyoung Kim	
Dr In Taek Kim	Kyungpook National University Hospital, Daegu, Gyeongsangbuk-do, 700-721, Korea
Dr Dong Jin Kang	
Dr Soo Hyun Kwon	
Dr Ji Eun Lee	Pusan National University Hospital, Busan, 602-739, Korea
Dr Sung Who Park	
Dr Kang Yeun Pak	
Dr Ji Hun Song	Ajou University Hospital, Suwon-si, Gyeonggi-do, 16499, Korea
Dr IlSuk Yun	
Dr Seran Jang	
Dr Hosung Jin	
Dr Eoijong Seo	
Dr Jong Wan Kim	
Dr June-Gone Kim	Asan Medical Center, Seoul, 055 05, Korea
Dr Joo Yong Lee	
Dr Yoon Jeon Kim	

Dr Kyu Hyung Park	Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 13620, Korea
Dr SeJoon Woo	
Dr Hye Kyoung Hong	
Dr SeWoong Kang	Samsung Medical Center, Seoul, 063 51, Korea
Dr SangJin Kim	
Dr Ga Eun Cho	
Dr Jongmin Kim	
Dr Won Ki Lee	The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, 137-701, Korea
Dr Jae Hyung Lee	
Dr Min Sagong	Yeungnam University Hospital, Daegu, 42415, Korea
Dr Woohyok Chang	
Dr Jongwoo Kim	Kim's Eye Hospital, 136, Yeongshin-ro, Yeongdeungpo-gu, Seoul, South Korea
Dr Sung Won Cho	
Dr Jungil Han	
Dr JooYeon Kim	